About the job
AI in Residence is a highly selective role at the intersection of frontier machine learning and drug discovery. Designed as an industry alternative to a traditional postdoctoral position, the program is for exceptional researchers and engineers who want to apply advanced AI to real biomedical problems end to end, from data to deployed systems. Residents join a small cohort working on high-impact AI efforts across Xaira. You'll collaborate closely with AI scientists, research engineers, and drug discovery teams to design, build, and ship machine learning capabilities that directly influence therapeutic programs. This is hands-on, system-level work with real scientific consequence.
Responsibilities
Develop and advance ML models for protein and antibody design using biophysical data, affinity data, library display data, protein structure datasets, and protein sequence datasets
Design and implement scalable pipelines for data curation, training, evaluation, and inference integrated into discovery workflows
Own projects end-to-end: problem framing → prototyping → validation → deployment
Evaluate robustness and reliability (generalization, uncertainty, failure modes), plus interpretability where it supports scientific decision-making
Contribute technical leadership by proposing new directions, shaping platform capabilities, and raising engineering/research standards through collaboration
Qualifications
Minimum
Recent MS or PhD graduates (or equivalent research experience) in ML/AI, computational biology, biomedical engineering, or related fields
Evidence of research excellence through high-quality publications or artifacts
Demonstrated ability to lead substantial technical work with originality—new modeling ideas, rigorous experiments, or production-grade systems adopted by others
Motivation to translate rigorous research into reliable, deployable AI systems that support therapeutic discovery
Preferred
Top venues (e.g., NeurIPS, ICML, ICLR, CVPR, ACL; Nature Methods, Cell Systems) are a plus
Strong preprints, open-source contributions, or shipped systems with demonstrated impact are equally compelling